Cardinal Health stock gains support from strong cash flow and dividend

Cardinal Health stock trades near recent highs as investors digest fresh cash flow figures, dividend payments and a solid balance sheet heading into late 2026.

Cardinal Health stock (ISIN US14149Y1082) is trading near elevated levels in early September 2026, with recent data showing a closing price of 234.55 USD as of August 28, 2026 and a modest after-hours pullback to 232.01 USD according to market data from a major US financial portal. As of September 2, 2026, investors are focusing on the companys latest fiscal 2026 cash flow figures, dividend payments and analyst assessments.

Cash flow and balance sheet underpin valuation

Fresh commentary on the healthcare distributor landscape highlights that in fiscal 2026 Cardinal Health generated about 5.0 billion USD of adjusted free cash flow and ended the year with 4.9 billion USD of cash, according to an analysis summarized by a recent balance sheet review published on September 2, 2026. For investors, this combination of high cash levels and strong free cash flow provides a buffer against industry pricing pressure and supports ongoing shareholder returns. Compared with historical periods when cash balances were lower, the current figures indicate a more conservative financial profile heading into late 2026.

In addition to cash and free cash flow, the capital structure remains a key topic. While the recent analysis focuses on Cardinal Health in the context of broader healthcare peers, the 5.0 billion USD of adjusted free cash flow in fiscal 2026 signals that the company can fund both debt reduction and shareholder distributions while still investing in growth initiatives. This level of free cash flow also offers reassurance that the current equity valuation is backed by tangible cash generation rather than purely by multiple expansion.

Dividend and analyst view support sentiment

The company continues to return capital to shareholders via dividends, with a quarterly payout of approximately 0.516 USD per share and an annualized distribution of about 2.06 USD as highlighted in an overview of Cardinal Healths stock performance and dividend history on a large US financial news and data site updated on September 2, 2026. At a share price near the mid 230 USD range in late August 2026, this implies a dividend yield just under 1 percent, which is modest but signals consistent income for long term holders. For income oriented investors, the stability of this payout, combined with the strong free cash flow, is an important part of the investment case.

Analyst sentiment also remains constructive. A fresh ownership filing summary from early September 2026 notes that Cardinal Health currently carries an average analyst rating of Moderate Buy and an average price target of 266.56 USD, according to data compiled by a US equity research aggregation platform on September 2, 2026. Relative to a recent opening level of 239.25 USD cited in the same report, this average target implies upside potential of about 11 percent. For comparison, the same financial data overview indicates that Cardinal Health has delivered a one year total return of 65.50 percent versus 19.45 percent for the SP 500 index as of September 2, 2026, underscoring how strongly the stock has outperformed the broader US market over the past 12 months.

Radiopharmaceutical services as a growth area

Beyond its core distribution business, Cardinal Health is positioning itself in radiopharmaceutical services and nuclear medicine logistics. A new white paper published on September 2, 2026 outlines how the company supports radiopharmaceutical therapy programs with guidance on radiation safety, operational workflows and regulatory compliance, according to a professional article highlighting Cardinal Healths latest guidance. For hospitals and imaging centers, these services help reduce implementation risk when starting or expanding therapeutic nuclear medicine offerings.

For investors, radiopharmaceutical logistics and services are particularly interesting because they can command higher margins than traditional wholesale distribution. By leveraging its nationwide network and regulatory expertise, Cardinal Health can create sticky customer relationships in this niche. Although the latest white paper does not include specific revenue numbers, it underscores managements focus on specialized solutions that complement the companys scale in drug distribution and medical products. Over time, successful expansion in this area could support revenue growth and margin stability relative to more commoditized segments.

Stock performance and investor perspective

In terms of recent performance, Cardinal Healths stock has delivered robust gains in 2026. Data from a major US financial site shows that as of September 2, 2026 the company posted a year to date total return of 20.05 percent and a one year return of 65.50 percent, compared with 11.94 percent and 19.45 percent respectively for the SP 500 index in the same periods, according to the performance table in the stock overview updated on September 2, 2026. This means Cardinal Health has outperformed the broader US market by about 45 percentage points over the past 12 months. Such outperformance often raises the bar for future results, as expectations embedded in the share price move higher.

The same overview highlights that the stock recently traded at 244.96 USD as of September 2, 2026 during US market hours. When compared with the after hours level of 232.01 USD seen as of August 28, 2026 on another charting portal, this indicates that the stock has moved in a range of roughly 230 to 245 USD in late August and early September 2026. For investors observing technical levels, this range provides a reference for near term support and resistance while they assess how upcoming earnings updates or guidance changes might influence the next leg of the share price.

Medical products portfolio underpins long term growth

One representative product area within Cardinal Healths portfolio is its range of sterile surgical products and procedural kits, which are used by hospitals and outpatient centers in the United States and internationally. These products, along with the companys medication management solutions and supply chain services, form a recurring revenue base that complements the more volatile dynamics of pharmaceutical distribution. As healthcare providers increasingly seek integrated supply chain partners, such product and service combinations can enhance customer loyalty and support long term contracts.

Although the latest white paper on radiopharmaceutical therapy focuses on specialized therapies rather than core surgical products, it still demonstrates how Cardinal Health leverages its expertise in handling sensitive medical materials. Investors tracking the business mix will pay attention to how much incremental revenue and margin contributions these higher value segments can deliver over time relative to traditional volume driven distribution.

Cardinal Health stock and current valuation

From a market perspective, Cardinal Health stock recently closed at 234.55 USD on August 28, 2026, with an after hours quote of 232.01 USD, according to the charting section of a major US financial portal. As of September 2, 2026, the same portal reports a spot price of 244.96 USD during market hours, suggesting that the stock has gained about 4.4 percent over these few trading sessions. While exact valuation multiples are not detailed in the latest day filtered data, the combination of strong free cash flow, dividend payments, and a moderate buy consensus rating indicates that many investors view the shares as supported by underlying fundamentals.

Key data for Cardinal Health

• Company: Cardinal Health Inc.
• ISIN: US14149Y1082
• Ticker: CAH
• Trading venue: NYSE
• Price (as of August 28, 2026, 16:00): 234.55 USD
• Market capitalization: not specified in available same day sources
• Sector / Industry: Health care distribution and services
• Index membership: SP 500